Fine Capital Partners, L.P. Viking Therapeutics, Inc. Transaction History
Fine Capital Partners, L.P.
- $702 Million
- Q3 2024
A detailed history of Fine Capital Partners, L.P. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Fine Capital Partners, L.P. holds 44,000 shares of VKTX stock, worth $2.16 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
44,000Holding current value
$2.16 Million% of portfolio
0.07%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VKTX
# of Institutions
474Shares Held
66.2MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$499 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$296 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$230 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$104 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$92.1 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.77B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...